$CETY

Clean Energy Technologies, Inc. (CETY): Entry into a Material Definitive Agreement

Clean Energy Technologies, Inc. (CETY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective August 10, 2026, Clean Energy Technologies, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with Pacific Pier Capital II, LP, a Delaware limited partnership (“ Pacific Pier ”), purs

Original reporting
Published Aug 14, 2026, 4:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CETY
Neutral
medium confidence
Mentioned
$CETY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CETYNeutralMed
01

Why it matters

A convertible promissory note financing can change the capital structure immediately and affect expectations for future dilution and balance-sheet risk. The market will likely price the probability and timing of conversion versus repayment.

02

Market read

This is a fresh SEC filing disclosing a new convertible debt instrument and related unregistered issuance mechanics, which can drive near-term trading around dilution and financing risk.

03

What to watch

Traders should focus on the missing Exhibit A and Note terms: conversion price/discount, valuation cap, interest rate, maturity, and any redemption or anti-dilution provisions.

Relevance 6/10Novelty 7/10Timing: filed Aug 14, 2026, after-hours/late session context

Background

The 8-K reports entry into a material definitive agreement and creation of a direct financial obligation, plus unregistered equity sales (Reg D Rule 506(b) context).

Company-level read

Ticker impact

$CETYNeutralMedium confidence
Context

CETY entered a material definitive securities purchase agreement for a $178,410 convertible promissory note with Pacific Pier Capital II.

Expected impact

Likely modest negative-to-neutral bias until conversion terms, discount, and dilution mechanics are fully digested.

Evidence & confidence

The 8-K is a primary disclosure of a capital raise structure (convertible note). The excerpt does not include conversion price/discount, maturity, or conversion caps, limiting precision on dilution and downside risk.

Market effects

Adds another example of small-cap clean-energy financing via convertible notes, reinforcing dilution overhang risk in the group.

No clear regional spillover beyond US micro/small-cap credit and equity financing sentiment.

Limited global relevance; this is company-specific financing.

Counterpoint

If the note’s conversion terms are favorable (no large discount, limited shares on conversion), the overhang could be smaller than typical convertible-debt fears.

Key entities

  • Clean Energy Technologies, Inc.

    Subject company filing the 8-K and issuing the convertible promissory note.

  • Pacific Pier Capital II, LP

    Purchaser of the note under the securities purchase agreement.

Related articles

$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.